Regeneron, Sanofi begin testing use of Arthritis Drug Kevzara to treat COVID-19 Medical Dialogues Bureau18 March 2020 12:24 PM ISTKevzara is a fully-human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor.The use of...
Regeneron partners with US to develop treatment for coronavirus Medical Dialogues Bureau7 Feb 2020 9:30 AM ISTUS: The United States is working with a pharmaceutical company to develop a treatment for the 2019 Novel Coronavirus, using a class of drug that has...
Sanofi loses German patent case against Amgen over cholesterol drug Praluent Medical Dialogues Bureau9 Jun 2019 9:30 AM ISTIn the latest setback for Sanofi in the drawn-out patent dispute with Amgen, which is selling its rival drug Repatha, the German court ruled that...
Sanofi to pay Regeneron $462 million in revised immuno-oncology deal Farhat Nasim9 Jan 2019 9:15 AM ISTSanofi will pay Regeneron $462 million representing the balance of payments due under their original deal, which covers the Sanofi share of the...
Novartis posts eye drug data amid play for Eylea's turf Ruby Khatun Khatun14 Nov 2017 9:45 AM ISTZURICH: Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new...
Regeneron third-quarter profit easily tops Street view on Eylea, Dupixent sales Ruby Khatun Khatun11 Nov 2017 9:30 AM ISTRegeneron Pharmaceuticals Inc on Wednesday reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand...
DBV Technologies peanut allergy drug fails key study Ruby Khatun Khatun23 Oct 2017 9:15 AM ISTDBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study, sending its...
Regeneron, Sanofi asthma drug data fails to excite investors Ruby Khatun Khatun13 Sept 2017 1:42 PM ISTPARIS: Shares of Regeneron Inc and Sanofi SA slid on Monday after late-stage trial data for their asthma drug, dupilumab, fell short of investor...
